Market Analysis - Lipids 2017
Lipid issue are the expansive term for variations from the norm of cholesterol and triglycerides. Lipid variations from the norm are connected with an expanded danger for vascular illness, and particularly heart assaults and strokes. Anomalies in lipid issue are a mix of hereditary inclination and in addition the way of dietary admission. Numerous lipid issue are connected with being overweight. Lipid issue might likewise be connected with different sicknesses including diabetes. There is gathering prove that administration of cholesterol and triglyceride issue is connected with the lessened danger for heart assaults and strokes.
Global Market Analysis of Lipids 2017:
The economic burden of lipid disorders is substantial because of the impact of lipid levels on the risk of cardiovascular disease and coronary heart disease events. The direct and indirect costs of all types of cardiovascular disease in 2015 were estimated to be $706.2 billion. The cost of cardiovascular disease exceeds that of any other high-cost medical conditions. For example, in 2008, the estimated total cost of all cancers was $228 billion and in 2007, the cost attributable to diabetes mellitus was $174 billion.
Heart disease and stroke are not only a major cause of premature death in persons younger than 65 years but also are major causes of serious disability in the United States. The indirect costs of cardiovascular disease, including those related to lost productivity, are enormous. It is estimated that the indirect cost of cardiovascular disease will total more than $279.1 billion in 2014.
The cost of implementing a lipid screening program varies by location, provider base, method of screening, which cholesterol measurements are taken, and other factors. The average cost of a single cholesterol or lipid profile test is relatively low but the cumulative costs of screening can be substantial, especially if all recommended screening and follow-up procedures are followed. In 2008, the private-sector cost of annual visits to lower LDL cholesterol averaged $74 per session.
Estimated Cost of Counseling and Treatment:
The total cost of reducing low-density lipoprotein includes the costs of physician services, lifestyle counseling, screening, case finding and monitoring, dietary and exercise modifications, medications, and treating side effects. The annual cost of statin drugs to reduce low-density lipoprotein cholesterol levels can range from $1,082 to $1,543 per year. The cost of follow-up or treatment-related appointments varies by type of provider, location, and practice setting. Although the cost of reducing low-density lipoprotein cholesterol levels can be high, it is much lower than the direct and indirect costs of cardiovascular disease.
In 2002, the National Cholesterol Education Program (NCEP) panel found that, on the basis of current retail prices for lipid-lowering drugs, low-density lipoprotein-lowering drug therapy is highly cost-effective for persons with established coronary heart disease (including a prior coronary heart disease event); cost-effective for the primary prevention of coronary heart disease in persons with a coronary heart disease risk equivalent (the person does not have coronary heart disease but does have an absolute 10-year risk of developing major coronary events, such as myocardial infarction and coronary death, equal to that of persons with coronary heart disease), and those at high risk for coronary heart disease; and acceptable for the primary prevention of coronary heart disease in persons whose 10-year risk of "hard coronary heart disease" (heart attack and death from coronary heart disease) is between 10% and 20%.
The National Cholesterol Education Program recommends using dietary therapy, which is more cost-effective than low-density lipoprotein-lowering drugs, as the first-line therapy in persons with a 10-year risk of coronary heart disease that is less than 10% per year.
Today 56% of grown-ups and almost 38% of youngsters battle with overweight and corpulence .If heftiness rates stay reliable, by 2030, 51 percent of the populace will be obese. Twenty years prior, no state had a stoutness rate above 15 percent. Today there are 41 states with corpulence rates more than 25 percent, as recorded by the Trust for European's Health. Subsequent to 1980, the rate of weight in youngsters and teenagers has practically tripled.72% of more seasoned men and 67% of more seasoned ladies are presently overweight or large. Heftiness is connected to more than 60 constant ailments. By European Association for the Study of Obesity, 428,000 Europeans kick the bucket of malignancy every year, around 33% of these tumor passings are connected to overabundance body weight, poor sustenance and/or physical idleness. More than 75 percent of hypertension cases are straightforwardly connected to weight. Around 66% of European grown-ups with sort 2 diabetes are overweight or have heftiness.